Categories AlphaGraphs, Health Care

Infographic: Highlights from Gilead Sciences (GILD) Q2 2020 earnings

Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and earnings estimates for the quarter.

GILD shares fell over 2% immediately following the announcement. The stock has gained 11% since the beginning of this year.

GIlead sciences Q2 2020 earnings

Looking forward to listening to management/ analysts comments on Q2 results? Stay tuned here for Gilead Science Q2 2020 earnings call transcript

CEO Daniel O’Day said, “We are also making important progress with our pipeline. In addition to the critical work of advancing remdesivir, we have continued to strengthen our presence in immuno-oncology. This includes six immuno-oncology agreements this year and the recent FDA approval for TecartusTM in mantle cell lymphoma.”

Prior performance

[irp posts=”67604″]

____

Most Popular

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Target (TGT): A look at some of the challenges faced by the retailer in 3Q24

Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top